Lysosomal-Based Degradation Technology Development
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
BOC Sciences provides integrated lysosomal-based degradation technology development services for researchers seeking to eliminate disease-relevant proteins that are difficult to address through conventional inhibition or proteasome-dependent degradation alone. By leveraging lysosome-targeting and autophagy-related mechanisms, we support the design, synthesis, validation, and optimization of degraders for extracellular proteins, membrane-associated proteins, intracellular proteins, protein aggregates, and selected organelle-related targets. Our solutions cover multiple modalities, including LYTAC degradation technology development, AUTAC degradation technology development, ATTEC degradation technology development, and AbTAC degradation technology development, helping clients select the most appropriate strategy based on target location, ligand availability, degradation mechanism, cellular context, and research objectives.
Services
BOC Sciences' Comprehensive Lysosomal-Based Degradation Development Services
Target Suitability and Degradation Strategy Assessment
Lysosomal-based degradation is highly dependent on target localization, internalization potential, ligand accessibility, trafficking route, and degradation compartment compatibility. We begin each project by evaluating whether a target is better suited for receptor-mediated lysosomal delivery, autophagy-mediated degradation, antibody-guided internalization, or another lysosome-related strategy.
Target localization and biological function analysis
Extracellular, membrane, cytosolic, aggregate, and organelle-associated target evaluation
Receptor-mediated uptake and lysosomal trafficking feasibility assessment
Different lysosomal degradation technologies solve different target problems. We help clients compare LYTAC, AUTAC, ATTEC, AbTAC, and related strategies to determine which format is most compatible with the target's molecular features, cellular distribution, biological pathway, and available ligand resources.
LYTAC strategy for extracellular and membrane-associated proteins
AUTAC strategy for autophagy-mediated degradation of intracellular proteins or organelle-related targets
ATTEC strategy for LC3-associated degradation of selected proteins or aggregates
AbTAC strategy for antibody-guided degradation of membrane proteins
Target-Binding Ligand and Recognition Module Design
A successful lysosomal degrader requires a target-recognition module with sufficient binding affinity, selectivity, and accessibility. Depending on the modality, we support small-molecule ligand design, peptide ligand design, antibody or antibody-fragment strategy planning, and ligand optimization for extracellular or intracellular degradation systems.
Small-molecule, peptide, antibody-related, and conjugatable ligand evaluation
Binding site accessibility and conjugation feasibility analysis
Affinity, selectivity, and cellular engagement optimization
Lysosome-Targeting Ligand and Trafficking Design
For lysosome-based degradation, the lysosome-directing component must guide the target into the correct cellular uptake and trafficking pathway. We support the selection and optimization of lysosome-targeting motifs, receptor-binding ligands, autophagy-recruiting motifs, and antibody-based internalization strategies according to the intended degradation mechanism.
Lysosome-targeting receptor engagement strategy
Endocytosis and lysosomal trafficking design considerations
Autophagy pathway recruitment and LC3-related strategy planning
Antibody-mediated internalization and degradation strategy support
Linker, Conjugation, and Molecular Architecture Optimization
The linker and conjugation site can strongly influence degrader stability, internalization, target engagement, lysosomal delivery, and degradation efficiency. We provide systematic optimization of linker length, flexibility, polarity, chemical stability, and conjugation position to improve the performance of lysosomal degraders.
Conjugation site evaluation for small molecules, peptides, and antibody-related formats
Hydrophilicity, steric spacing, and stability optimization
Multi-format degrader architecture design
Synthesis, Bioconjugation, and Candidate Preparation
We provide chemistry and conjugation support for lysosomal degrader discovery, from focused molecule synthesis to antibody-ligand conjugation and analog library preparation. Our team helps clients translate conceptual designs into testable molecules suitable for biological evaluation and iterative optimization.
Small-molecule lysosomal degrader synthesis
Peptide- and ligand-conjugate preparation
Antibody- or protein-based degrader conjugation strategy support
Focused analog series preparation for SAR exploration
Are You Facing These Challenges in Lysosomal-Based Degradation Projects?
Uncertainty about whether the target should be addressed by LYTAC, AUTAC, ATTEC, AbTAC, or another degradation approach
Difficulty in designing ligands for extracellular, membrane-associated, aggregate-prone, or intracellular targets
Limited understanding of receptor-mediated uptake, autophagy recruitment, or lysosomal trafficking requirements
Our Solutions for Lysosomal-Based Degradation Development Challenges
Lysosomal degradation projects often fail not because the target is biologically irrelevant, but because the degradation route, molecular architecture, cellular trafficking pathway, or assay design is not properly matched to the target. BOC Sciences provides mechanism-driven solutions to help clients make clear technical decisions and accelerate degrader optimization.
Solution for Modality Selection
We compare target localization, accessibility, internalization route, ligand availability, and degradation endpoint to determine whether LYTAC, AUTAC, ATTEC, AbTAC, or another lysosome-related strategy is more suitable. For example, a soluble extracellular protein may require a receptor-mediated LYTAC approach, while an aggregate-prone intracellular protein may be better explored through autophagy-associated mechanisms.
Solution for Ligand and Target Engagement
We help clients identify, design, and optimize target-binding ligands with appropriate affinity, selectivity, and conjugation potential. When ligand information is limited, we can combine literature analysis, virtual screening, molecular docking for protein-ligand, and structure-guided optimization to generate practical starting points.
Solution for Internalization and Lysosomal Trafficking
For membrane and extracellular targets, we evaluate whether receptor engagement can drive productive internalization and lysosomal transport. For intracellular or aggregate-related targets, we analyze autophagy recruitment, LC3-associated mechanisms, and degradation pathway compatibility to avoid designs that bind the target but fail to reach the degradation compartment.
Solution for Activity Validation and Mechanistic Confirmation
We design fit-for-purpose assays to distinguish true lysosomal degradation from simple target blocking, cellular redistribution, or expression changes. Our validation strategies may include degradation kinetics, dose-response analysis, lysosomal pathway confirmation, target rescue experiments, and cellular functional readouts.
Choose BOC Sciences to Build a Target-Matched Lysosomal Degradation Strategy
From target feasibility assessment and molecular design to synthesis, assay validation, and candidate optimization, BOC Sciences helps research teams develop lysosomal degraders with clearer mechanisms, stronger degradation performance, and more actionable decision-making data.
LYTAC Platform for Extracellular and Membrane Proteins
LYTACs are designed to direct extracellular or membrane-associated proteins toward lysosomal degradation through receptor-mediated internalization. We support target ligand selection, lysosome-targeting ligand strategy, linker optimization, conjugate synthesis, internalization analysis, and degradation validation.
Suitable for selected soluble extracellular proteins and cell-surface proteins
Supports research on targets not easily addressed by intracellular proteasome-based degraders
Requires careful receptor engagement, uptake, and trafficking evaluation
AUTAC Platform for Autophagy-Mediated Degradation
AUTAC-based strategies use autophagy-associated mechanisms to promote degradation of selected intracellular proteins or organelle-related targets. We help clients evaluate target feasibility, design bifunctional molecules, optimize linker architecture, and establish degradation assays that reflect autophagic pathway engagement.
Useful for targets where autophagy recruitment is mechanistically relevant
Supports exploration of protein, aggregate, and organelle-associated degradation
Requires pathway-specific validation to confirm autophagy dependence
ATTEC Platform for LC3-Associated Target Degradation
ATTEC strategies aim to connect disease-relevant targets with autophagy-related degradation machinery, often through LC3-associated mechanisms. BOC Sciences supports ligand discovery, molecular design, binding evaluation, degradation activity assays, and iterative optimization for ATTEC-related research projects.
Applicable to selected intracellular proteins and aggregation-prone targets
Requires balanced engagement of both target and autophagy machinery
Can be combined with structure-guided and cell-based validation workflows
AbTAC Platform for Antibody-Guided Membrane Protein Degradation
AbTAC approaches use antibody-based target recognition to promote the degradation of cell-surface proteins through intracellular trafficking and lysosomal routing. We provide strategy planning for antibody or antibody-fragment selection, conjugation design, receptor engagement, internalization assessment, and target degradation analysis.
Suitable for selected membrane proteins with accessible extracellular domains
Supports projects where antibody recognition provides selectivity advantages
Requires optimization of internalization, trafficking, and degradation readouts
Workflow
End-to-End Lysosomal-Based Degradation Development Workflow
01
Inquiry and Project Requirement Collection
We collect target information, known ligands, available biological data, desired degradation outcome, preferred modality, assay requirements, and project timeline.
02
Target and Modality Feasibility Assessment
We evaluate target localization, ligand accessibility, internalization potential, lysosomal or autophagy pathway compatibility, and technical risks.
03
Technical Proposal and Development Strategy
We define the recommended degradation modality, molecular design route, assay plan, deliverables, and staged decision points.
04
Recognition Module and Targeting Module Design
We design or optimize the target-binding ligand, lysosome-targeting component, autophagy-recruiting motif, antibody-related module, or other required recognition elements.
05
Linker and Molecular Architecture Optimization
We optimize linker length, flexibility, polarity, steric spacing, conjugation site, and overall degrader architecture to improve cellular performance.
06
Synthesis, Conjugation, and Sample Preparation
We prepare designed degraders or focused analog series and verify chemical identity, purity, and suitability for biological testing.
07
Activity Evaluation and Mechanistic Validation
We assess target engagement, internalization, degradation efficiency, dose response, degradation kinetics, pathway involvement, and cellular functional impact.
08
Optimization, Data Interpretation, and Candidate Delivery
We interpret experimental results, refine the design strategy, identify promising candidates, and provide clear data packages for subsequent research decisions.
Evaluation
Assays and Evaluation Capabilities for Lysosomal Degraders
Reliable validation is critical for lysosomal degradation projects because target loss may be influenced by binding, internalization, trafficking, expression regulation, or pathway-specific degradation. BOC Sciences provides customized assay solutions to help distinguish true degradation from indirect cellular effects.
Target Engagement and Binding Evaluation
We evaluate target-degrader interaction using biochemical or cellular methods, including binding affinity measurement, ligand binding studies, and target engagement assays.
Cellular Uptake and Trafficking Assessment
We assess internalization, cellular distribution, lysosomal co-localization, and time-dependent trafficking behavior to determine whether the degrader reaches the intended degradation compartment.
Degradation Activity and Kinetic Analysis
We support degradation ability assay workflows, including concentration-response studies, time-course analysis, degradation window assessment, and target recovery evaluation.
Cell-Based Functional Readouts
We provide live-cell assay support and customized functional assays to connect target degradation with downstream biological effects in relevant cellular models.
Advantages
Advantages of Lysosomal-Based Degradation Technology
Expands Degradation Beyond Cytosolic Targets
Lysosomal-based strategies can address selected extracellular and membrane-associated proteins that are not readily accessible to intracellular proteasome-dependent degradation.
Enables Degradation of Larger or Complex Targets
The lysosomal pathway can support clearance of protein complexes, aggregates, and selected surface-bound targets that may be poorly suited to traditional small-molecule inhibition.
Uses Cellular Trafficking for Target Clearance
By exploiting endocytosis, lysosomal routing, or autophagy-related transport, this technology can redirect disease-relevant targets toward natural cellular degradation compartments.
Supports Functional Protein Removal
Instead of only blocking target activity, lysosomal degradation aims to reduce the target protein itself, enabling deeper evaluation of protein-loss biology and pathway dependence.
Applications
Research Applications Supported by Our Lysosomal Degradation Platform
Extracellular Protein Degradation
Degradation of selected secreted proteins, soluble ligands, or extracellular disease-associated proteins
LYTAC-based exploration of targets inaccessible to intracellular degradation systems
Evaluation of ligand binding, receptor-mediated uptake, and lysosomal delivery
Support for mechanism-focused extracellular protein clearance studies
Membrane Protein Degradation
Degradation of selected receptors, transporters, immune-checkpoint-related proteins, or disease-associated membrane proteins
LYTAC or AbTAC strategy design for accessible extracellular domains
Internalization, trafficking, and lysosomal co-localization assessment
Functional readout development for receptor depletion studies
Protein Aggregates and Neurodegeneration-Related Targets
Exploration of autophagy-associated degradation for aggregate-prone proteins
ATTEC or AUTAC strategy evaluation for selected intracellular targets
Support for cellular models involving protein accumulation or impaired clearance
Degradation and cellular phenotype assessment in relevant research systems
Oncology, Immunology, and Cell Biology Research
Target degradation studies involving cell-surface receptors or signaling proteins
Mechanistic research on lysosome-dependent target elimination
Custom degrader design for difficult target classes and emerging biology
Case
Client Success Stories: Lysosomal-Based Degradation Technology Development
Project Background
An oncology-focused biopharmaceutical company aimed to target the EGFR using a degradation strategy. While intracellular degraders like PROTACs are effective for cytoplasmic targets, the client needed a solution to address the extracellular domain of EGFR and its membrane-bound variants. The primary challenge lay in designing a bifunctional molecule (LYTAC) that could effectively bridge the extracellular target protein to the Cation-Independent Mannose-6-Phosphate Receptor (CI-M6PR) for lysosomal trafficking.
Our Support
To overcome the limitations of traditional inhibitors, we developed a customized LYTAC development plan. We synthesized a series of chemically defined M6P-glycan ligands with high affinity for CI-M6PR and conjugated them to EGFR-targeting antibodies via site-specific click chemistry. By optimizing the Glycan-to-Antibody Ratio (GAR) and linker hydrophilicity, we enhanced the endocytosis efficiency of the complex. The project utilized Flow Cytometry and Confocal Microscopy to track the internalization and lysosomal localization of the target. Ultimately, we delivered three lead LYTAC candidates that demonstrated significant EGFR protein depletion in high-expression cell lines, achieving superior results compared to the naked antibody.
Client Testimonial
The BOC Sciences team demonstrated exceptional expertise in glycan chemistry and lysosomal trafficking pathways. Their ability to precisely engineer the LYTAC structure allowed us to target extracellular proteins that were previously difficult to degrade, significantly accelerating our early-stage pipeline.
Project Background
A research institute focused on neurodegenerative diseases sought to develop a novel ATTEC to clear mutant Huntingtin (mHTT) protein aggregates. Unlike PROTACs, which rely on the proteasome, the client required a lysosomal-mediated autophagy approach to handle large, insoluble protein clusters. The difficulty was in identifying a "tether" molecule that could selectively bind both the mHTT protein and the autophagosome-resident protein LC3 without interfering with normal cellular autophagy flux.
Our Support
We provided a comprehensive ATTEC development service, starting with a high-throughput screening of a fragment-based library to identify novel LC3-binding motifs. After identifying a high-affinity LC3-tether, we utilized our medicinal chemistry platform to link it with a selective mHTT-binding warhead. We addressed the challenge of molecular "hook effects" by systematically varying the linker rigidity. To validate the mechanism, we performed dual-fluorescence LC3-GFP-mCherry assays and electron microscopy to confirm the engulfment of mHTT into autophagosomes. The resulting ATTEC molecules successfully reduced mHTT levels by over 60% in patient-derived neuronal models while maintaining cell viability, providing a robust proof-of-concept for the client's therapeutic hypothesis.
Client Testimonial
Working with BOC Sciences was a game-changer for our autophagy project. Their systematic approach to ATTEC design—from LC3-binder screening to complex validation assays—provided us with the high-quality data needed to secure the next round of funding and advance our research into pathogenic protein clearance.
Why Choose Us
Why Choose BOC Sciences for Your Lysosomal-Based Degradation Project?
Multi-Platform Lysosomal Degradation Expertise
We support LYTAC, AUTAC, ATTEC, AbTAC, and related lysosome- or autophagy-associated degradation strategies for diverse target classes.
Target-Matched Strategy Development
We select degradation approaches based on target localization, accessibility, ligand availability, internalization potential, and pathway compatibility.
We help clients interpret whether observed target reduction is related to lysosomal degradation, autophagy involvement, trafficking efficiency, or other cellular effects.
Flexible Service Modules
Clients can access individual modules such as feasibility analysis, ligand design, conjugation, degradation assays, or full end-to-end development support.
Actionable Results for R&D Decisions
We deliver clear experimental data and practical recommendations to support target prioritization, degrader optimization, and next-step project planning.
Lysosomal-Based Degradation Technology is a drug discovery strategy that uses the cell’s lysosomal pathway to degrade disease-relevant proteins or extracellular and membrane-associated targets. Unlike conventional inhibitors that mainly block target activity, this approach focuses on removing target proteins from the biological system. It is especially valuable for targets that are difficult to modulate with traditional small molecules. By combining target-binding ligands, linkers, lysosomal trafficking mechanisms, and degradation assays, this technology provides new opportunities for early-stage drug discovery in oncology, immunology, neurodegeneration, and other therapeutic research areas.
How Does Lysosomal Degradation Differ from PROTAC?
Lysosomal degradation and PROTAC are both targeted protein degradation strategies, but they rely on different cellular pathways. PROTAC molecules typically use the ubiquitin-proteasome system and are more commonly applied to intracellular proteins. Lysosomal-based degradation, by contrast, leverages endocytosis and lysosomal trafficking, making it highly relevant for membrane proteins, extracellular proteins, secreted proteins, and larger protein complexes. For drug development teams, the choice between these approaches depends on target location, ligand availability, internalization potential, degradation kinetics, and the overall developability profile of the designed degrader.
Which Targets Suit Lysosomal Degradation Strategies?
Targets suitable for lysosomal degradation strategies often include membrane receptors, extracellular disease-associated proteins, secreted proteins, and certain protein complexes that are difficult to address with conventional inhibitors. These targets usually require efficient binding, internalization, trafficking, and delivery to lysosomes for productive degradation. BOC Sciences supports drug discovery programs by offering target assessment, ligand design, linker optimization, degrader synthesis, and in vitro evaluation services, helping clients determine whether a target is appropriate for lysosomal degradation-based development at an early research stage.
What Matters in Lysosome-Targeting Degrader Development?
Developing lysosome-targeting degraders requires careful consideration of target-binding affinity, internalization efficiency, lysosomal localization, linker length, linker stability, cellular activity, selectivity, and degradation durability. A successful molecule must not only recognize the target but also promote effective cellular uptake and lysosomal delivery. BOC Sciences provides integrated support across molecular design, custom synthesis, structural optimization, and degradation activity testing, enabling drug discovery teams to refine early degrader concepts and make more informed decisions during lead identification and optimization.
How Are Lysosomal Degrader Activities Evaluated?
Evaluating lysosomal degrader activity typically requires a multidimensional assay strategy, including target protein level measurement, dose-response profiling, time-dependent degradation analysis, cellular localization studies, internalization assessment, and lysosomal pathway dependency confirmation. A single assay readout is often not sufficient to demonstrate that a molecule works through a lysosomal mechanism. BOC Sciences can help clients design fit-for-purpose evaluation workflows based on target biology and degrader format, generating reliable data to support mechanism exploration, structure-activity relationship studies, and further molecular optimization.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Target Engagement and Binding Evaluation
